#1 Clinical Trials Search in Europe

Quavonlimab

Quavonlimab is an investigational drug being studied in clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC). These trials are exploring how Quavonlimab works in combination with other cancer drugs, particularly pembrolizumab, to potentially improve outcomes for patients with advanced cancers. The studies are evaluating the safety, effectiveness, and optimal dosing of these drug combinations in different patient groups.

Table of Contents

What is Quavonlimab?

Quavonlimab, also known as MK-1308, is an investigational drug being studied for the treatment of various advanced cancers[1]. It belongs to a class of medications called immunotherapy drugs, which work by helping the body’s immune system fight cancer cells. Quavonlimab is currently being tested in clinical trials and is not yet approved for general use[2].

How Quavonlimab Works

Quavonlimab is designed to enhance the body’s immune response against cancer cells. While the exact mechanism is not fully described in the provided information, immunotherapy drugs like Quavonlimab typically work by targeting specific proteins or pathways that cancer cells use to evade the immune system. By blocking these mechanisms, Quavonlimab may help the immune system recognize and attack cancer cells more effectively[1].

Conditions Treated with Quavonlimab

Based on the clinical trials information, Quavonlimab is being studied for the treatment of:

  • Advanced solid tumors: These are cancers that form solid masses in the body and have spread or become difficult to treat with standard therapies[1].
  • Advanced non-small cell lung cancer (NSCLC): This is a type of lung cancer that accounts for the majority of lung cancer cases[2].
  • Small cell lung cancer (SCLC): Another type of lung cancer that tends to grow and spread faster than NSCLC[1].
  • Melanoma: A type of skin cancer that has become resistant to other immunotherapy treatments[1].

Quavonlimab in Combination Therapy

One of the key aspects of Quavonlimab’s development is its use in combination with other cancer treatments. The clinical trials are testing Quavonlimab in combination with:

  • Pembrolizumab: Another immunotherapy drug that has shown effectiveness in treating various cancers[1].
  • Lenvatinib: A targeted therapy drug that can help stop the growth and spread of cancer cells[2].

These combinations are being studied to determine if they can provide better outcomes for patients than single-drug treatments.

Ongoing Clinical Trials

Quavonlimab is currently being evaluated in several clinical trials:

  • KEYNOTE-495 (NCT03516981): This study is investigating the use of Quavonlimab in combination with Pembrolizumab for advanced non-small cell lung cancer. The trial is using biomarkers (specific biological indicators) to determine which patients might benefit most from the treatment[2].
  • MK-1308-001 (NCT03179436): This trial is studying Quavonlimab in combination with Pembrolizumab for various advanced solid tumors. It includes different phases to determine the best dosage and assess the drug’s effectiveness[1].

Potential Side Effects

As with all medications, Quavonlimab may cause side effects. The clinical trials are closely monitoring for any adverse events (AEs), which are undesirable experiences associated with the use of a medical product. These can range from mild to severe. Some potential side effects being monitored include:

  • Immune-related adverse events: Since Quavonlimab affects the immune system, it may cause the immune system to attack healthy cells in the body.
  • Fatigue
  • Nausea
  • Decreased appetite
  • Skin reactions

It’s important to note that the full range of side effects is still being studied, and patients in clinical trials are closely monitored for any unexpected reactions[1][2].

Future Prospects

The development of Quavonlimab represents an exciting area of cancer research. If the clinical trials show positive results, Quavonlimab could potentially become a valuable treatment option for patients with advanced cancers, particularly those who have not responded well to other treatments.

Researchers are particularly interested in how Quavonlimab performs in combination with other drugs and how it might be tailored to patients based on specific biomarkers. This approach, known as precision medicine, aims to provide the most effective treatment for each individual patient[2].

As Quavonlimab is still in the investigational stage, it’s important for patients to discuss current treatment options with their healthcare providers and to stay informed about the progress of these clinical trials.

Aspect Details
Drug Name Quavonlimab (MK-1308)
Type of Drug Investigational biological therapy
Main Combination Often studied in combination with pembrolizumab
Cancer Types Advanced solid tumors, including NSCLC, SCLC, and melanoma
Administration Intravenous (IV) infusion
Trial Phases Phase 1/2 and Phase 2 studies
Primary Outcomes Safety, tolerability, pharmacokinetics, and preliminary efficacy
Secondary Outcomes Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS)
Biomarker Strategy Some trials use biomarker-based classification (e.g., GEP and TMB) to guide treatment

FAQ

  • What is Quavonlimab? Quavonlimab is an investigational drug being studied for the treatment of advanced solid tumors. It is often tested in combination with other cancer drugs, particularly pembrolizumab.
  • What types of cancer is Quavonlimab being studied for? Quavonlimab is being studied for various advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and melanoma.
  • How is Quavonlimab administered? Quavonlimab is typically administered through intravenous (IV) infusion. The dosing schedule can vary depending on the specific clinical trial and combination therapy being studied.
  • What are the main goals of the clinical trials involving Quavonlimab? The main goals include assessing the safety and tolerability of Quavonlimab in combination with other drugs, determining the optimal dosing, evaluating its effectiveness in treating various cancers, and studying how it affects the body (pharmacokinetics).
  • Are there any known side effects of Quavonlimab? As Quavonlimab is still in clinical trials, the full range of potential side effects is not yet known. The trials are carefully monitoring for adverse events and safety concerns. Patients in the trials are closely observed for any unexpected reactions or side effects.

Ongoing Clinical Trials on Quavonlimab

  • Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Greece Hungary Italy Poland Spain

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Hungary The Netherlands Poland Spain

  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy

  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Hungary The Netherlands Poland Spain

  • Study on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases

    Not recruiting

    1 1 1
    Investigated drugs:
    France Greece Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Poland Spain

  • Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Croatia Czechia Denmark Finland France Germany +8

  • Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Estonia France Germany Greece +7

Glossary

  • Advanced Solid Tumors: Cancers that have spread from where they started to other parts of the body and are usually not curable with standard treatments.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Dose Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
  • Gene Expression Profile (GEP): A measurement of the activity of genes in a tissue sample, which can provide information about the biological processes occurring in that tissue.
  • Tumor Mutational Burden (TMB): A measurement of the number of mutations carried by tumor cells, which can be used to predict how likely a patient is to respond to certain treatments.

References